The crucial role of dopamine (DA) in movement control is illustrated by the spectrum of motor disorders caused by either a deficiency or a hyperactivity of dopaminergic transmission in the basal ganglia. The degeneration of nigrostriatal DA neurons in Parkinson's disease causes poverty and slowness of movement. These symptoms are greatly improved by pharmacological DA replacement with l-3,4-dihydroxy-phenylalanine (l-DOPA), which however causes excessive involuntary movements in a majority of patients. l-DOPA-induced dyskinesia (abnormal involuntary movements) provides a topic of investigation at the interface between clinical and basic neuroscience. In this article, we review recent studies in rodent models, which have uncovered two princi...
Copyright © Experimental Neurobiology 2020. Motor symptoms in Parkinson\u27s disease (PD) are direct...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
Understanding the biological mechanisms of l-dopa-induced motor complications is dependent on our ab...
Understanding the biological mechanisms of l-dopa-induced motor complications is dependent on our ab...
The nigrostriatal dopamine (DA) system has an essential role in the selection and control of movemen...
The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment...
The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson's disease (PD...
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkins...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
L-DOPA-induced dyskinesia is a major complication of L-DOPA pharmacotherapy in Parkinson's disease, ...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Copyright © Experimental Neurobiology 2020. Motor symptoms in Parkinson\u27s disease (PD) are direct...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
Understanding the biological mechanisms of l-dopa-induced motor complications is dependent on our ab...
Understanding the biological mechanisms of l-dopa-induced motor complications is dependent on our ab...
The nigrostriatal dopamine (DA) system has an essential role in the selection and control of movemen...
The dopamine (DA) precursor, 3,4-dihydroxyphenyl-L-alanine (L-DOPA), is the most effective treatment...
The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson's disease (PD...
L-3,4-dihydroxyphenylalanine (L-DOPA) remains the most efficacious drug for the treatment of Parkins...
Long-term levodopa (l-dopa) treatment in patients with Parkinson´s disease (PD) is associated with t...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
L-DOPA-induced dyskinesia is a major complication of L-DOPA pharmacotherapy in Parkinson's disease, ...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Though a multi-facetted disorder, Parkinson’s disease is prototypically characterized by neurodegene...
Copyright © Experimental Neurobiology 2020. Motor symptoms in Parkinson\u27s disease (PD) are direct...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...
L-DOPA (L-3,4-dihydroxyphenylanalnine) therapy is indispensible in the treatment of Parkinson's dise...